Human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) are increasingly being used for cardiac safety evaluation, disease modeling, and regenerative medicine. To date, the majority of cardiotoxicity studies have examined the acute drug effects. However, these studies lack information on the chronic effects of cardiotoxic compounds. Here, motion vector prediction (MVP) method was employed to invasively quantify contractile function over 10 days, then to test whether nobiletin has a protective effect against thecardiotoxicity of 8-days exposure to doxorubicin and erlotinib. The MVP method showed that doxorubicin (0.1 - 0.3 μM) significantly reduced contractility compared to erlotinib (0.3 - 3 μM), which has no cardiotoxicity, when administered for more than 5 days, and that the simultaneous addition of 0.03 μM nobiletin significantly reduced this cardiac depression by doxorubicin (0.1 - 0.3 μM). These results suggest that nobiletin is protective against the cardiotoxic effect of doxorubicin, and are promising for future drug discovery applications.